a b s t r a c t
Observational studies have linked lower omega-3 (n-3) polyunsaturated fatty acids (PUFAs) and higher omega-6 (n-6) PUFAs with inflammation and depression, but randomized controlled trial (RCT) data have been mixed. To determine whether n-3 decreases proinflammatory cytokine production and depressive and anxiety symptoms in healthy young adults, this parallel group, placebo-controlled, double-blind 12-week RCT compared n-3 supplementation with placebo. The participants, 68 medical students, provided serial blood samples during lower-stress periods as well as on days before an exam. The students received either n-3 (2.5 g/d, 2085 mg eicosapentaenoic acid and 348 mg docosahexanoic acid) or placebo capsules that mirrored the proportions of fatty acids in the typical American diet. Compared to controls, those students who received n-3 showed a 14% decrease in lipopolysaccharide (LPS) stimulated interleukin 6 (IL-6) production and a 20% reduction in anxiety symptoms, without significant change in depressive symptoms. Individuals differ in absorption and metabolism of n-3 PUFA supplements, as well as in adherence; accordingly, planned secondary analyses that used the plasma n-6:n-3 ratio in place of treatment group showed that decreasing n-6:n-3 ratios led to lower anxiety and reductions in stimulated IL-6 and tumor necrosis factor alpha (TNF-a) production, as well as marginal differences in serum TNF-a. These data suggest that n-3 supplementation can reduce inflammation and anxiety even among healthy young adults.
The reduction in anxiety symptoms associated with n-3 supplementation provides the first evidence that n-3 may have potential anxiolytic benefits for individuals without an anxiety disorder diagnosis. ClinicalTrials.gov identifier: NCT00519779.
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1. Introduction
Inflammation, mental and physical health, and omega-3
Chronic inflammation has been linked to a broad spectrum of health problems including cardiovascular disease, stroke, and rheumatoid arthritis (Shelton and Miller, 2010; Wall et al., 2010; Wilson, 2008) . Large population studies suggest that greater fish consumption may help control or protect against the onset of these and other inflammatory conditions (Breslow, 2006; Larsson et al., 2011; Wall et al., 2010) . Fish oil is the prime source for the two key omega-3 (n-3) polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA). Diets high in n-3 PUFAs may also benefit mood and behavior, particularly depression.
Epidemiological data have demonstrated inverse relationships between annual fish consumption and depression-the more fish eaten, the lower the prevalence of serious clinical depression as well as depressive symptoms (Golding et al., 2009; Hibbeln, 1998; Tanskanen et al., 2001) . Observational studies have also associated lower n-3 PUFA plasma levels with depressed mood in both psychiatric and nonpsychiatric populations (Kiecolt-Glaser et al., 2007; Lin et al., 2010; Tiemeier et al., 2003) . However, a recent meta-analysis of randomized controlled trials concluded that n-3 PUFA supplementation benefited clinically depressed individuals, but not those with less severe depressed mood (Appleton et al., 2010) .
Comorbid depressive and anxiety disorders occur frequently, and some symptoms are common to both (Ross, 2009); thus,
